Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 180
- Registration Number
- NCT03710824
- Locations
- 🇬🇷
University Hospital of Heraklion, University Pulmonology Cl, Heraklion, Greece
🇬🇷Univ. Gen. Hosp. of Ioannina, Ioannina, Greece
🇬🇷Gen. Hosp. of Chest Diseases "Sotiria", Univ. Resp. Med., Athens, Greece
Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
- Conditions
- Neoplasm Metastasis
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 212
- Registration Number
- NCT03697304
- Locations
- 🇺🇸
Florida Cancer Specialists-Fort Myers-52980, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists-Saint Petersburg-52979, Saint Petersburg, Florida, United States
🇺🇸Florida Cancer Specialists-Sarasota-61670, Tallahassee, Florida, United States
Characteristics of Pts Initiating Spiriva Respimat in Asthma
- Conditions
- Asthma
- Interventions
- Device: Spiriva Respimat
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 116133
- Registration Number
- NCT03692676
- Locations
- 🇩🇪
Boehringer Ingelheim, Ingelheim, Germany
A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT03684265
- Locations
- 🇷🇺
City Clinical Hospital named after V.P. Demikhova Department of Health of Moscow, Moscow, Russian Federation
A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17
- Registration Number
- NCT03675581
- Locations
- 🇪🇸
Hospital Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
🇳🇱Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
A Study in Healthy Men to Test How BI 730357 is Processed by the Body
- Conditions
- Healthy
- Interventions
- Drug: BI 730357 mixed with [C-14]BI 730357 BS
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT03664011
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4819
- Registration Number
- NCT03663569
- Locations
- 🇧🇬
MBAL Kiro Popov EOOD, Karlovo, Bulgaria
🇧🇬MBAL Sv. Ivan Rilski EOOD, Kozloduj, Bulgaria
🇧🇬MBAL Sliven to VMA Sofia, Sliven, Bulgaria
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 103
- Registration Number
- NCT03659136
- Locations
- 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇺🇸Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, United States
A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body
- Conditions
- Healthy
- Interventions
- Drug: BI 425809 mixed with [C-14] BI425809
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT03654170
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 79
- Registration Number
- NCT03648541
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Southern Star Research Institute, LLC, San Antonio, Texas, United States